Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

The study, “Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease ...

Ever since Alois Alzheimer first described the neurological changes that characterize the disease that now bears his name, amyloid plaques have been a central focus of AD research. By the early ...

due to AD and mild AD dementia stages of the disease. These studies validate both the amyloid hypothesis and the therapeutic approach of Aβ plaque removal; and yet we know the story is much more ...

A University of Kansas study of rare gene mutations that cause hereditary Alzheimer's disease shows these mutations disrupt the production of a small sticky protein called amyloid. Plaques ...

As the disease progresses to moderate dementia, damage in areas of the brain that control language, reasoning, conscious ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data ...

Amyloid builds up in the spaces between brain cells, forming distinctive plaques that are one of ... battle to find treatments that change Alzheimer's disease is changing," Dr Cath Mummery ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A study from Wake Forest University has found that drinking alcohol, even in moderate amounts, may speed up the progression ...

The neurodegenerative disorder affects millions of Americans, and its impact varies significantly across the country.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.